SPOTLIGHT -
Slideshow
Author(s):
Can dietary supplementation decrease the risk of transition to psychosis?
FDA Committees Vote to Dismiss Clozapine REMS
Treating ‘Morally Objectionable’ Patients
Long-Acting Injectables and a Team-Driven Approach for Schizophrenia Treatment
More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle
Emraclidine for Schizophrenia Fails to Meet Primary Endpoints in Phase 2 EMPOWER Trials
Schizophrenia Pharmacology: Version 2.0